Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/ijms24021040
Keywords
chitosan; arginine; modification; siRNA; transfection
Ask authors/readers for more resources
The modification of low-molecular-weight chitosan with arginine resulted in the successful creation of arginine-chitosan nanoparticles. These nanoparticles were able to encapsulate and deliver siRNA safely to leukemia cells, making them a potential tool for future therapies targeting specific genes. This study identified arginine-chitosan nanoparticles for the first time and explored their ability to deliver Rhoa siRNA into T-cell acute lymphoblastic leukemia cells.
The modification of chitosan (CS) has greatly expanded its application in the field of medicine. In this study, low-molecular-weight chitosan was modified with arginine (Arg) by a simple method. The identification by the Fourier transform infrared spectra (FTIR) showed that Arg was successfully covalently attached to the CS. Interestingly, Arg-CS was identified as nanoparticles by atomic force microscopy (AFM) and transmission electron microscopy (TEM), whose particle size was 75.76 +/- 12.07 nm based on Dynamic Light Scattering (DLS) characterization. Then, whether the prepared Arg-CS nanoparticles could encapsulate and deliver siRNA safely was investigated. Arg-CS was found to be able to encapsulate siRNAs in vitro via electrostatic interaction with siRNA; the Arg-CS/siRNA complex was safe for L1210 leukemia cells. Therefore, modification of chitosan by Arg produces novel nanoparticles to deliver siRNA into leukemia cells. This is the first time to identify Arg-CS as nanoparticles and explore their ability to deliver Rhoa siRNA into T-cell acute lymphoblastic leukemia (T-ALL) cells to advance therapies targeting Rhoa in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available